Seeking Alpha

Galena Biopharma GALE +5.4%) moves up after releasing positive data from its phase 1/2 clinical...

Galena Biopharma GALE +5.4%) moves up after releasing positive data from its phase 1/2 clinical trial of tumor drug NeuVax. According to the trial, the drug showed a consistent reduction of circulating tumor cells in vaccinated patients. Final results will be reported at the San Antonio Breast Cancer Symposia in December 2012.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)